1: Sharif NA, Williams GW, Crider JY, Xu SX, Davis TL. Molecular pharmacology of the DP/EP2 class prostaglandin AL-6598 and quantitative autoradiographic visualization of DP and EP2 receptor sites in human eyes. J Ocul Pharmacol Ther. 2004 Dec;20(6):489-508. doi: 10.1089/jop.2004.20.489. PMID: 15684809.
2: Toris CB, Zhan GL, Feilmeier MR, Camras CB, McLaughlin MA. Effects of a prostaglandin DP receptor agonist, AL-6598, on aqueous humor dynamics in a nonhuman primate model of glaucoma. J Ocul Pharmacol Ther. 2006 Apr;22(2):86-92. doi: 10.1089/jop.2006.22.86. PMID: 16722794.
3: Hellberg MR, McLaughlin MA, Sharif NA, DeSantis L, Dean TR, Kyba EP, Bishop JE, Klimko PG, Zinke PW, Selliah RD, Barnes G, DeFaller J, Kothe A, Landry T, Sullivan EK, Andrew R, Davis AA, Silver L, Bergamini MV, Robertson S, Weiner AL, Sallee VL. Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. Surv Ophthalmol. 2002 Aug;47 Suppl 1:S13-33. doi: 10.1016/s0039-6257(02)00293-x. PMID: 12204698.
4: Hellberg MR, Conrow RE, Sharif NA, McLaughlin MA, Bishop JE, Crider JY, Dean WD, DeWolf KA, Pierce DR, Sallee VL, Selliah RD, Severns BS, Sproull SJ, Williams GW, Zinke PW, Klimko PG. 3-Oxa-15-cyclohexyl prostaglandin DP receptor agonists as topical antiglaucoma agents. Bioorg Med Chem. 2002 Jun;10(6):2031-49. doi: 10.1016/s0968-0896(02)00016-0. PMID: 11937363.
5: Sharif NA. Identifying new drugs and targets to treat rapidly elevated intraocular pressure for angle closure and secondary glaucomas to curb visual impairment. Exp Eye Res. 2023 Mar 21:109444. doi: 10.1016/j.exer.2023.109444. Epub ahead of print. PMID: 36958427.
6: Sharif NA, Davis TL, Williams GW. Ocular hypotensive DP-class prostaglandin receptor affinities determined by quantitative autoradiography on human eye sections. J Ocul Pharmacol Ther. 2005 Apr;21(2):121-32. doi: 10.1089/jop.2005.21.121. PMID: 15857278.